Review of Immune effector Cell-Associated Neurotoxicity Syndrome (ICANS)
Evidence to Action: Official Journal of MDCalc · 15.05.2026 · 012026 (01)
DOI: 10.65357/001c.158530 ↗Kurz gefasst
Fachartikel in der Zeitschrift Evidence to Action: Official Journal of MDCalc, online erschienen am 15.05.2026. Verfasst von Austin Wesevich.
Abstract (Originalsprache)
The American Society for Transplantation and Cellular Therapy (ASTCT) developed this consensus grading system based on prior Common Terminology Criteria for Adverse Events (CTCAE) and Immune Effector Cells Therapy Toxicity Assessment and Management (CARTOX) grading systems. Grade of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) should guide management.
Zitieren
APA
Wesevich, A. (2026). Review of Immune effector Cell-Associated Neurotoxicity Syndrome (ICANS). Evidence to Action: Official Journal of MDCalc, 012026(01). https://doi.org/10.65357/001c.158530
Vancouver
Wesevich A. Review of Immune effector Cell-Associated Neurotoxicity Syndrome (ICANS). Evidence to Action: Official Journal of MDCalc. 2026;012026(01). doi:10.65357/001c.158530
BibTeX
@article{Wesevich2026,
author = {Wesevich, Austin},
title = {Review of Immune effector Cell-Associated Neurotoxicity Syndrome (ICANS)},
journal = {Evidence to Action: Official Journal of MDCalc},
year = {2026},
volume = {012026},
number = {01},
doi = {10.65357/001c.158530}
}
EUVIMED